
Agreement - February 1, 2017
InDex Pharmaceuticals enters agreement
InDex Pharmaceuticals Holding has entered an agreement for services with the global contract research organization (CRO) PAREXEL for the implementation of the CONDUCT study. The CONDUCT is a phase IIb dose optimisation study with the drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis. According to the agreement, the first patient […]